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ABSTRACT
7KHSURJQRVWLFVLJQL¿FDQFHRISHOYLFDQGSDUDDRUWLFO\PSKDGHQHFWRP\GXULQJ
primary debulking surgery for advanced-stage ovarian cancer remains unclear. This 
study aimed to evaluate the survival impact of lymph node dissection (LND) in patients 
treated with optimal cytoreduction for advanced ovarian cancer. Data from 158 
consecutive patients with stage IIIC–IV disease who underwent optimal cytoreduction 
FPZHUHREWDLQHGYLDUHWURVSHFWLYHFKDUWUHYLHZ3DWLHQWVZHUHFODVVL¿HGLQWRWZR
JURXSVO\PSKQRGHVDPSOLQJ/16QRGHFRXQWDQG/1'QRGHFRXQW
Progression-free (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier 
method. Among the included patients, 96 and 62 patients underwent LND and LNS as 
primary debulking surgery, respectively. There were no differences in the extent of 
debulking surgical procedures, including extensive upper abdominal surgery, between 
WKHJURXSV3DWLHQWVZKRXQGHUZHQW/1'KDGDPDUJLQDOO\VLJQL¿FDQWO\LPSURYHG3)6
3 DQGVLJQL¿FDQWO\LPSURYHG263FRPSDUHGZLWKWKRVHZKR
underwent LNS. In a subgroup with negative lymphadenopathy on preoperative 
computed tomography scans, revealed LND correlated with a better PFS and OS 
(P = 0.042, 0.001, respectively). Follow-ups of subsequent recurrences observed 
DVLJQL¿FDQWO\ORZHUQRGDOUHFXUUHQFHUDWHDPRQJSDWLHQWVZKRXQGHUZHQW/1'$
PXOWLYDULDWHDQDO\VLVLGHQWL¿HG/1'DVDQLQGHSHQGHQWSURJQRVWLFIDFWRUIRU3)6KD]DUG
UDWLR>+5@FRQ¿GHQFHLQWHUYDO>&,@±DQG26+5
CI, 0.137–0.456). In conclusion, systematic LND might have therapeutic value and 
improve prognosis for patients with optimally cytoreduced advanced ovarian cancer.
INTRODUCTION
More than two-thirds of patients with epithelial ovarian 
cancer (EOC) have advanced disease at the time of diagnosis; 
hence, EOC remains a major cause of gynecologic cancer-
related mortality [1]. Currently, the primary standard treatment 
for advanced-stage EOC comprises debulking surgery and 
adjuvant taxane- and platinum-based chemotherapies [2]. 
Radical debulking surgery is a critical treatment strategy for 
advanced ovarian cancer, and several studies have supported 
the importance of maximal cytoreductive surgical efforts to 
minimize residual disease [3, 4].
Notably, the role of systematic lymph node dissection 
(LND) in the treatment of stage IIIC–IV ovarian cancer 
remains controversial because this procedure does not 
LQÀXHQFH WKH VXUJLFDO VWDJH DQG LWV WKHUDSHXWLF EHQH¿W
is uncertain [5–7]. Consensus has not yet been reached 
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UHJDUGLQJWKHHI¿FDF\RIWKLVSURFHGXUHGHVSLWHWKHVWDWXV
of retroperitoneal lymph node metastasis was reported as a 
major risk factor for poor prognosis [8–10]. Current National 
Comprehensive Cancer Network (NCCN) guidelines do 
not recommend systematic LND other than the removal of 
suspicious and/or enlarged nodes in patients with advanced 
disease. In addition, 2 previous randomized controlled trials 
5&7VIDLOHGWRLGHQWLI\DVLJQL¿FDQWEHQH¿WRIV\VWHPDWLF
LND for overall survival (OS) [5, 11], whereas retrospective 
studies have demonstrated the potential favorable impact of 
this procedure on OS [9, 10, 12, 13]].
Previous studies were, however, performed before 
radical surgery was generally accepted as a standard 
therapy for advanced ovarian cancer [14, 15]. Therefore, 
the role of systematic LND merits further investigation 
in the era of radical surgery. The present study aimed to 
evaluate the survival impact of systematic LND as part 
of optimal primary debulking surgery for the treatment of 
advanced ovarian cancer.
RESULTS
Among 274 patients who were diagnosed with 
advanced epithelial ovarian cancer at our institution from 
2006 to 2015, optimal cytoreduction was achieved in 175 
(63.9%); of these, the lymphadenectomy status could 
EH LGHQWL¿HG LQ  SDWLHQWV 7KH FOLQLFRSDWKRORJLFDO
characteristics of the patients included in this study are listed 
in Table 1. A total of 158 consecutive patients with optimally 
cytoreduced primary International Federation of Gynecology 
and Obstetrics (FIGO) stage IIIC and IV disease who had 
received adjuvant platinum-based chemotherapy during the 
study period were analyzed. Of these patients, 62 (39.2%) 
underwent lymph node sampling (LNS) and 96 (60.8%) 
underwent LND (including both pelvic and para-aortic 
lymphadenectomy) as part of primary debulking surgery. The 
groups were similar with respect to age, preoperative cancer 
antigen (CA) 125 level, suspected lymph node metastasis on 
preoperative computed tomography (CT) scan, histology, 
FIGO stage, and grade. In addition, the groups did not differ 
with regard to the radicality of surgical procedures, including 
bowel resection, diaphragm resection, peritonectomy, and 
video-assisted thoracoscopic surgery (VATS), but did differ 
VLJQL¿FDQWO\ LQ WHUPV RI WKH QXPEHU RI GLVVHFWHG O\PSK
nodes (P < 0.001; Table 2). Furthermore, the rates of no 
gross residual disease after debulking surgery did not differ 
VLJQL¿FDQWO\EHWZHHQWKHJURXSV3 
A Kaplan–Meier survival analysis indicated an 
apparently favorable progression-free survival (PFS) in 
the LND group, compared to the LNS group, and this 
GLIIHUHQFHZDVPDUJLQDOO\VLJQL¿FDQW3 ,QWKH
VXEJURXSDQDO\VLV/1'FRUUHODWHG VLJQL¿FDQWO\ZLWKD
better PFS when compared with LNS among patients with 
negative lymphadenopathy on a preoperative CT scan 
3 )LJXUH,QDGGLWLRQSDWLHQWVZKRXQGHUZHQW
/1'KDGDVLJQL¿FDQWO\LPSURYHG26ZKHQFRPSDUHGWR
those who underwent LNS (P < 0.001), and a subgroup 
DQDO\VLVIRXQGWKDW/1'FRUUHODWHGZLWKDVLJQL¿FDQWO\
longer OS, regardless of the suspected lymphadenopathy 
VWDWXVRQDSUHRSHUDWLYH&7VFDQ3 )LJXUH
A comparison of the characteristics of patients who 
experienced subsequent recurrence is shown in Table 3. 
$OWKRXJKWKHUHFXUUHQFHUDWHVGLGQRWGLIIHUVLJQL¿FDQWO\
between the LNS and LND groups (54.8% vs. 58.3%, P 
 DFRPSDULVRQRIWKHUHFXUUHQFHVLWHVUHYHDOHGD
VLJQL¿FDQWO\KLJKHUQRGDOUHFXUUHQFHUDWHLQSDWLHQWVZKR
underwent LNS, compared to those who underwent LND 
YV3 ,QDVXEJURXSDQDO\VLV/1'
correlated with a lower nodal recurrence rate, regardless 
of the suspected lymphadenopathy status determined by 
preoperative CT scan (LNS vs. LND: 61.1% vs. 32.4% in 
WKH,PDJHVXEJURXS3 YVLQWKH
,PDJHVXEJURXS3 
Univariate and multivariate Cox regression analyses 
of PFS and OS in all patients are shown in Table 4. The 
PXOWLYDULDWH DQDO\VLV RI 3)6 LGHQWL¿HG D SUHRSHUDWLYH
CA 125 level >500 U/ml, histologically proven nodal 
PHWDVWDVLVDQGV\VWHPDWLF/1'DVVLJQL¿FDQWIDFWRUV3 
0.03, 0.003, and 0.045, respectively). The hazard ratio (HR) 
RI/1'IRU3)6ZDVFRQ¿GHQFHLQWHUYDO>&,@
±7KHPXOWLYDULDWHDQDO\VLVIRU26LGHQWL¿HG
DJHDQGV\VWHPLFO\PSKDGHQHFWRP\DVVLJQL¿FDQWIDFWRUV3
 DQG3UHVSHFWLYHO\DQGWKH+5RI/1'
for OS was 0.250 (95% CI, 0.137–0.456).
DISCUSSION
,Q WKH FXUUHQW VWXG\ ZH REVHUYHG D VLJQL¿FDQW
LPSURYHPHQW LQ 26 DQG PDUJLQDOO\ VLJQL¿FDQW
improvement in PFS in patients who underwent pelvic 
and para-aortic systematic LND during primary optimal 
debulking surgery for advanced-stage ovarian cancer. 
Moreover, in a subgroup analysis according to the gross 
lymphadenopathy status as assessed by preoperative 
&7VFDQQLQJVLJQL¿FDQWEHQH¿FLDOHIIHFWVRIV\VWHPDWLF
LND on both PFS and OS were observed in patients 
with negative lymphadenopathy on a preoperative CT 
VFDQ7KH IDYRUDEOH HI¿FDF\RI V\VWHPDWLF/1'PLJKW
be attributed to the contribution of this procedure to the 
detection and removal of occult and chemoresistant lymph 
node metastases, as inferred from our data regarding 
the characteristics of subsequent nodal recurrence, the 
incidence of which might be decreased by LND.
Multidisciplinary treatment, which includes 
cytoreductive surgery and platinum-based chemotherapy, 
is the mainstay of management for women with advanced-
stage ovarian cancer [16]. Although medical treatment is 
nearly homogenous, surgical treatment is individualized 
according to the disease extent and patient characteristics 
and therefore remains heterogeneous. Moreover, the 
role of complete lymphadenectomy in a primary staging 
operation with the intent to gain information regarding 
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prognostic relevance remains under debate by many 
authors [5, 6, 10, 11, 13, 17–22], and therefore a consensus 
regarding the therapeutic role of this procedure has not 
been established, particularly after radical surgery was 
accepted as standard EOC management.
Previous studies have demonstrated the potential 
importance of systematic LND for the detection of occult 
lymph node metastases [5, 11, 18]. In two previous RCTs, 
patients with EOC who were treated with systematic LND 
had a higher rate of histologically proven lymph node 
metastasis when compared with those who underwent 
macroscopic lymph node removal (22% vs. 9% for early-
stage disease; 70% vs. 42% for advanced-stage disease) 
[5, 11], suggesting a potential increase in the opportunity 
to detect occult lymph node metastasis via systematic 
LND in patients with advanced ovarian cancer. This 
K\SRWKHVLV ZDV YHUL¿HG E\ D SUHYLRXV VWXG\ ZKHUHLQ
the reported detection rates of lymph node metastasis in 
Table 1: Characteristics of patients in the study
Variables LNS (n = 62) LND (n = 96) P-value
Age, median (range) 53 (27-81) 55 (32-78) 0.359
BMI (kg/m2) 23.1 (11.6-35.3) 22.5 (17.5-31.4) 0.192
Preoperative serum CA 125 (U/
mL) 1643.6 (16.3–17223.1) 1637.1 (13.5–11582.7) 0.987
Suspected LN metastasis on CT scan
 Yes 30 (48.4%) 56 (58.3%) 0.22
 No 32 (51.6%) 40 (41.7%)
Histology
 Serous 45 (72.6%) 85 (88.5%) 0.182
 Mucinous 0 1 (1.0%)
 Endometrioid 7 (11.3%) 4 (4.2%)
 Clear cell 3 (4.8%) 3 (3.1%)
 Mixed 3 (4.8%) 2 (2.1%)
 Undifferentiated 1 (1.6%) 0
 Unknown 3 (4.8%) 1 (1.0%)
Stage
 IIIC 47 (75.8%) 74 (77.1%) 0.853
 IV 15 (24.2%) 22 (22.9%)
Tumor grade
 Grade 1 1 (1.6%) 6 (6.3%) 0.209
 Grade 2 21(33.9%) 39 (40.6%)
 Grade 3 40 (64.5%) 51 (53.1%)
LN metastasis
 Yes 33 (53.2%) 70 (72.9%) 0.011
 No 29 (46.8%) 26 (27.1%)
Residual disease
 NGR 11 (17.7%) 28 (29.2%) 0.141
 R < 0.5 cm 30 (48.4%) 33 (34.4%)
 R < 1 cm 21 (33.9%) 35 (36.5%)
LNS, lymph node sampling; LND, lymph node dissection; SD, standard deviation; N/A, not available; LN, lymph node, 
NGR, no gross residual disease; R, residual disease
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patients with peritoneally advanced ovarian cancer ranged 
from 48% to 75% [18]. Of note, the data from our study 
DOVRVXSSRUWWKLVK\SRWKHVLVYV3 
,QWKHSUHVHQWVWXG\WKHVHQVLWLYLW\DQGVSHFL¿FLW\
of a preoperative CT scan for the detection of lymph node 
metastasis were 65.0% and 65.5%, respectively. Among 86 
patients with suspected lymphadenopathy on preoperative 
CT scans, nodal metastasis was histologically proven in 
67 patients (77.9%). In addition, the false negative rate, 
or detection rate of occult lymph node metastasis among 
patients with preoperative CT scans indicating negative 
lymphadenopathy, was 50% (36 of 72 patients). This 
observation suggests that a negative preoperative imaging 
result on lymph node metastasis could not justify the 
omission of systematic LND during debulking surgery for 
advanced ovarian cancer.
Incompletely resected occult lymph node metastases 
may give rise to chemoresistance, a possibility that is 
supported by the “pharmacologic sanctuary hypothesis” 
of poor prognosis in patients with EOC with lymph 
QRGHLQYROYHPHQW6SHFL¿FDOO\WKLVK\SRWKHVLVVXJJHVWV
that the diminished blood supply of lymph node 
metastases might promote resistance to chemotherapy 
[23], and further implies that systematic LND might be 
a favorable prognostic factor in patients with advanced 
ovarian cancer who have an increased risk of occult 
lymph node metastasis [24]. Because ovarian cancer is 
known to spread simultaneously both intraperitoneally 
and retroperitoneally, the lymphatic spread of a tumor 
might persist despite achieving optimal cytoreduction of 
intraperitoneal dissemination, thus contributing to a poor 
prognosis [25].
$OWKRXJK RXU GDWD VXJJHVW EHQH¿WV RI V\VWHPDWLF
LND for patients with optimally cytoreduced advanced 
ovarian cancer, these data should be interpreted with 
caution. We attempted to minimize potential bias by 
accounting for all known prognostic variables associated 
with both the tumors and patients; however, selection bias 
regarding patient recruitment cannot be ruled out because of 
the retrospective nature of this study. Moreover, decisions 
regarding whether to perform systematic lymphadenectomy 
were made according to each surgeon’s discretion, rather 
WKDQUDQGRPDOORFDWLRQRUZHOOGH¿QHGFULWHULD
Notably, the prognostic relevance of lymphadenectomy 
is currently under investigation in the prospective phase III 
trial “Randomized, Multicentre Trial for Lymphadenectomy 
in Ovarian Neoplasms” (https://clinicaltrials.gov/ct2/show/
NCT00712218). This ongoing study compares the prognostic 
outcomes associated with systematic lymphadenectomy 
vs. no lymphadenectomy in patients without macroscopic 
UHVLGXDO LQWUDDEGRPLQDO WXPRUV WR DVVHVV WKH HI¿FDF\ RI
systematic pelvic and para-aortic lymphadenectomy. This 
trial is expected to clarify the status of this important issue.
In conclusion, the present study has demonstrated the 
potential therapeutic value of systematic LND with respect 
to improved prognosis following the optimal removal of 
intra-abdominal peritoneal metastases, regardless of the 
preoperatively suspected lymphadenopathy status on CT 
VFDQV 7KLV ¿QGLQJ PLJKW H[SODLQ WKH FRUUHODWLRQ RI D
lower nodal recurrence rate with systematic LND vs. LNS.
Table 2: Characteristics of surgical procedures applied to patients in this study
LNS (n = 62) LND (n = 96) P
Number of resected LNs 10 (0–19) 37 (20–97) <0.001
Radical surgery
 Bowel resection 15 (24.2%) 19 (19.8%) 0.511
 Diaphragm resection 14 (22.6%) 22 (22.9%) 1
 Peritonectomy 24 (38.7%) 32 (33.3%) 0.49
 VATS 4 (6.5%) 11 (11.5%) 0.294
 Ureter resection 3 (4.8%) 2 (2.1%) 0.381
 Liver resection 4 (6.5%) 3 (3.1%) 0.434
 Splenectomy 2 (3.2%) 8 (8.3%) 0.318
 Cholecystectomy 4 (6.5%) 2 (2.1%) 0.212
Residual disease
 NGR 11 (17.7%) 28 (29.2%) 0.141
 R < 0.5 cm 30 (48.4%) 33 (34.4%)
 R < 1 cm 21 (33.9%) 35 (36.5%)
LNS, lymph node sampling; LND, lymph node dissection; LN, lymph node; VATS, video-assisted thoracoscopic surgery; 
NGR, no gross residual disease; R, residual disease
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Figure 1: Comparison of PFS in patients who underwent LNS and LND. A. Overall analysis of PFS. Patients who underwent 
/1'KDGD IDYRUDEOH3)6ZLWKPDUJLQDO VLJQL¿FDQFH 3 B. Subgroup analysis of PFS according to lymphadenopathy status 
RQSUHRSHUDWLYH&7VFDQ ,Q WKH ,PDJH VXEJURXS/1'JURXSVKRZHGVLJQL¿FDQWO\ ORQJHU3)6 WKDQ WKH/16JURXSV >ORJUDQN WHVW
,PDJH/1'YV,PDJH/163 ,PDJH/1'YV,PDJH/163 @3)6SURJUHVVLRQIUHHVXUYLYDO/16O\PSK
node sampling; LND, lymph node dissection.
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Figure 2: Comparison of OS in patients who underwent LNS and LND. A. Overall analysis of OS. Patients who underwent 
/1' KDG D VLJQL¿FDQWO\ IDYRUDEOH 26 FRPSDUHG WR WKRVH WUHDWHG ZLWK /16 3  B. Subgroup analysis of OS according to 
O\PSKDGHQRSDWK\VWDWXVRQSUHRSHUDWLYH&7VFDQ%RWK/1'JURXSVKDGDVLJQL¿FDQWO\ORQJHU26UHODWLYHWRWKH/16JURXSVUHJDUGOHVV
RI WKHSUHRSHUDWLYH VXVSHFWHG O\PSKDGHQRSDWK\ VWDWXV >ORJUDQN WHVW ,PDJH/1'YV ,PDJH/163  ,PDJH/1'YV
,PDJH/163 @26RYHUDOOVXUYLYDO/16O\PSKQRGHVDPSOLQJ/1'O\PSKQRGHGLVVHFWLRQ
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Table 3: Characteristics of recurrence
 LNS (n = 62) LND (n = 96) P Image(+)/
LNS(n = 30)
Image(+)/
LND(n = 56)
P Image(-) /
LNS(n = 32)
Image(-) /
LND(n = 40)
P
Recurrence 34 (54.8%) 56 (58.3%) 0.665 19 (60.0%) 37 (66.1%) 0.576 16 (50.0%) 19 (47.5%) 0.833
Recurrence site in recurrent cases
 LN 21 (61.8%) 19 (33.9%) 0.01 11 (61.1%) 12 (32.4%) 0.043 10 (62.5%) 7 (36.8%) 0.13
  Isolated 
LN 6 (17.6%) 6 (10.7%) 0.358 3 (15.8%) 4 (10.8%) 0.671 3 (18.8%) 2 (10.5%) 0.642
  Peritoneal 
seeding 10 (29.4%) 23 (41.1%) 0.266 5 (26.3%) 16 (43.2%) 0.215 5 (31.2%) 7 (36.8%) 0.728
 Liver 11 (32.4%) 19 (33.9%) 1 7 (38.9%) 13 (35.1%) 0.786 4 (25.0%) 6 (31.6%) 0.668
 Lung 3 (8.6%) 3 (5.4%) 0.672 3 (15.8%) 2 (5.4%) 0.197 0 1 (5.3%) 0.352
LNS, lymph node sampling; LND, lymph node dissection; Image(+), positive lymphadenopathy on preoperative CT scan; 
Image(-), negative lymphadenopathy on preoperative CT scan; LN, lymph node
Table 4: Univariate and multivariate analyses of various factors for PFS and OS
No. of 
patients
PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age, years 
(continuous) 158 1.016 (0.994-1.039) 0.154 1.043 (1.013-1.075) 0.005 1.044 (1.014-1.075) 0.004
Histology
 Non-
serous 28 1 (Reference) 1 (Reference)
 Serous 124 1.226 (0.611-2.462) 0.567 1.072 (0.454-2.530) 0.874
Tumor grade
 Grade 1 7 1 (Reference) 1 (Reference)
 Grade 2-3 151 1.364 (0.576-3.186) 0.227 1.140 (0.345-3.765) 0.83
Preoperative CA 125, U/ml
  58 1 (Reference) 1 (Reference) 1 (Reference)
 >500 94 1.722 (1.030-2.881) 0.038 1.713 (1.053-2.789) 0.033 1.540 (0.782-3.033) 0.212
Suspected LN metastasis on preoperative imaging studies
 No 69 1 (Reference) 1 (Reference)
 Yes 83 1.326 (0.809-2.171) 0.263 1.461 (0.746-2.860) 0.269
LN metastasis
 No 55 1 (Reference) 1 (Reference) 1 (Reference)
 Yes 103 2.060 (1.162-3.651) 0.013 2.238 (1.304-3.841) 0.004 1.331 (0.628-2.820) 0.455
Residual disease
 NGR 39 1 (Reference) 1 (Reference)
 R < 1 cm 113 1.102 (0.604-2.011) 0.752 1.251 (0.498-3.142) 0.634
(Continued )
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MATERIALS AND METHODS
Study design
$ ÀRZ GLDJUDP RI WKH SDWLHQW VHOHFWLRQ SURFHVV
is presented in Figure 3. Patients who were diagnosed 
with advanced-stage (FIGO IIIC and IV) EOC from 
January 2006 to December 2015 and underwent optimal 
cytoreduction, or had residual disease of <1 cm were 
included in this study. The retrospective study protocol of 
this study was approved by our Institutional Review Board.
A retrospective chart review was performed to 
identify all patients who underwent primary debulking 
surgery, including hysterectomy, bilateral oophorectomy, 
omentectomy, and retroperitoneal lymph node excision 
with or without various radical surgeries (e.g., bowel 
resection, diaphragm resection, peritonectomy) and 
received adjuvant standard platinum-based chemotherapy. 
A gynecologic oncology team comprising 5 surgeons at a 
single institute conducted all procedures, and 2 dedicated 
radiologists at the same institute reviewed preoperative 
computed tomography (CT) scan data.
No. of 
patients
PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Lymphadenectomy
 LNS 58 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
 LND 94 0.613 (0.384-0.979) 0.041 0.629 (0.400-0.989) 0.048 0.310 (0.163-0.588) <0.001 0.250 (0.137-0.456) <0.001
3)6SURJUHVVLRQIUHHVXUYLYDO26RYHUDOOVXUYLYDO+5KD]DUGUDWLR&,FRQ¿GHQFHLQWHUYDO&$FDQFHUDQWLJHQ1*5QR
gross residual disease; R, residual disease; LNS, lymph node sampling; LND, lymph node dissection
Figure 3: Patient selection diagram. LNS, lymph node sampling; LND, lymph node dissection.
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To determine the therapeutic value of systematic 
/1'SDWLHQWVZHUHFODVVL¿HGLQWR/16DQG/1'JURXSV
[11, 26, 27]. Decisions regarding whether to perform LND 
or LNS were made according to each surgeon’s discretion. 
/16 FRPSULVHG QRGH VDPSOLQJ DQG EXON\ QRGH FP
UHPRYDOWRWDOUHVHFWHGQRGHFRXQW/1'ZDVGH¿QHG
as systematic lymphadenectomy (total resected node count: 
LQFOXGLQJERWKV\VWHPLFSHOYLFDQGSDUDDRUWLFO\PSK
node dissection. Systemic pelvic LND included the resection 
of all lymph nodes and fatty tissue between the external and 
internal iliac arteries from the bifurcation of the common 
LOLDFDUWHU\XSWRWKHFLUFXPÀH[YHLQDQGDERYHWKHREWXUDWRU
nerve. Systemic para-aortic LND included the resection of 
all lymph nodes and fatty tissue overlying the common iliac 
artery, vena cava, and aorta anteriorly up to the renal vessels 
and laterally to the edge of the psoas major muscle. The 
surgical procedures and characteristics of recurrence and 
prognosis were compared between the groups.
Additionally, a subgroup analysis was conducted 
to investigate the role of LND with respect to apparent 
nodal involvement on a preoperative CT scan. Both 
JURXSV GHVFULEHG DERYH ZHUH VWUDWL¿HG DFFRUGLQJ WR
the suspected lymphadenopathy status on preoperative 
CT scans. Image(+) indicated positive preoperatively 
VXVSHFWHGO\PSKDGHQRSDWK\GH¿QHGDVWKHGHWHFWLRQRI
O\PSKQRGHHQODUJHPHQWFPLQWKHORQJRUVKRUWD[LV
RQD&7VFDQ,PDJHZDVGH¿QHGDVDODFNRIVXVSHFWHG
lymphadenopathy on a preoperative CT scan.
Statistical analysis
IBM SPSS version 20 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for the statistical analysis. 
The Kolmogorov–Smirnov test was used to verify 
standard normal distributional assumptions. Pearson’s chi 
square test, Fisher’s exact test, and the Mann–Whitney 
U test were used in the univariate analysis. Survival 
outcomes were determined through a Kaplan–Meier 
survival analysis. Univariate and multivariate analyses of 
the effects of various prognostic factors on survival were 
performed using the Cox proportional hazards model. 
Multivariate analysis was performed with variables that 
FRQVLGHUHGVLJQL¿FDQWLQXQLYDULDWHDQDO\VLV$3YDOXHRI
ZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW
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